Bristol-Myers Squibb (BMS) has filed for approval of a fixed-dose combination of its HIV drug Reyataz with Gilead Sciences’ cobicistat in the US. The product combines BMS’ successful HIV protease ...
Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...
The FDA did not request additional clinical or non-clinical data US regulators have refused to file Bristol Myers Squibb and bluebird bio’s marketing application seeking approval of idecabtagene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback